Suissa et al. conducted a population-based cohort study using the U.K. Clinical Practice Research Datalink (CPRD) and observed no difference in breast cancer incidence between new users of SGLT2 and DPP-4 inhibitors, with a median follow-up of just 2.6 years, suggesting that SGLT2 inhibitors might not have any positive effects on the metabolic changes they are associated with [150]. This evidence concerns the gene SLC5A2 and breast cancer.